United Capital Financial Advisors LLC Invests $924,000 in Kenvue Inc. $KVUE

United Capital Financial Advisors LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, Holdings Channel reports. The firm bought 48,364 shares of the company’s stock, valued at approximately $924,000.

A number of other large investors also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership acquired a new position in Kenvue in the 2nd quarter valued at $6,528,000. Jump Financial LLC lifted its holdings in shares of Kenvue by 210.6% during the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after buying an additional 37,170 shares in the last quarter. AXA S.A. lifted its holdings in shares of Kenvue by 21.1% during the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after buying an additional 8,524 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after acquiring an additional 66,930 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Kenvue by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock valued at $39,217,000 after acquiring an additional 10,885 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $19.15 on Monday. The company has a market cap of $36.78 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 1.37 and a beta of 0.47. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $20.82. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The stock has a fifty day moving average price of $19.16 and a 200-day moving average price of $18.25.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.29 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were issued a $0.21 dividend. The ex-dividend date of this dividend was Wednesday, August 12th. This represents a $0.84 annualized dividend and a yield of 4.4%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 96.55%.

Wall Street Analyst Weigh In

KVUE has been the topic of several research reports. UBS Group decreased their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Barclays lifted their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Finally, Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.